ArticleJournal of immunology (Baltimore, Md. : 1950)2010
Surfactant protein-A inhibits mycoplasma-induced dendritic cell maturation through regulation of HMGB-1 cytokine activity.
Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Obese asthmatic patients have decreased surfactant protein A levels: Mechanisms and implications.The Journal of allergy and clinical immunology · 2018Trial
- Immune dysregulation inFrontiers in immunology · 2026Review
- The Immune Modulatory Role of Surfactants inJournal of inflammation research · 2025Review
- Small Peptide Derivatives Within the Carbohydrate Recognition Domain of SP-A2 Modulate Asthma Outcomes in Mouse Models and Human Cells.Frontiers in immunology · 2022Article
- CC16 Binding to αAmerican journal of respiratory and critical care medicine · 2021Article
- A Plausible Role for Collectins in Skin Immune Homeostasis.Frontiers in immunology · 2021Review
- A 20-Mer Peptide Derived from the Lectin Domain ofInfection and immunity · 2020Article
- High expression of HMGB1 in children with refractory Mycoplasma pneumoniae pneumonia.BMC infectious diseases · 2018Article
- The Emerging Roles of Surfactant Protein-A in Asthma.Journal of clinical & cellular immunology · 2018Article
- Genetic variation in SP-A2 leads to differential binding to Mycoplasma pneumoniae membranes and regulation of host responses.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- HMGB1 in health and disease.Molecular aspects of medicine · 2014Review
- Housing conditions modulate the severity of Mycoplasma pulmonis infection in mice deficient in class A scavenger receptor.Comparative medicine · 2014Article
- Novel role for surfactant protein A in gastrointestinal graft-versus-host disease.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Surfactant protein-A suppresses eosinophil-mediated killing of Mycoplasma pneumoniae in allergic lungs.PloS one · 2012Article
- The immunogenic involvement of miRNA-492 in mycoplasma pneumoniae infection in pediatric patients.Jornal de pediatriaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
During pulmonary infections, a careful balance between activation of protective host defense mechanisms and potentially injurious inflammatory processes must be maintained. Surfactant protein A (SP-A) is an immune modulator that increases pathogen uptake and clearance by phagocytes while minimizing lung inflammation by limiting dendritic cell (DC) and T cell activation. Recent publications have shown that SP-A binds to and is bacteriostatic for Mycoplasma pneumoniae in vitro. In vivo, SP-A aids in maintenance of airway homeostasis during M. pneumoniae pulmonary infection by preventing an overzealous proinflammatory response mediated by TNF-α. Although SP-A was shown to inhibit maturation of DCs in vitro, the consequence of DC/SP-A interactions in vivo has not been elucidated. In this article, we show that the absence of SP-A during M. pneumoniae infection leads to increased numbers of mature DCs in the lung and draining lymph nodes during the acute phase of infection and, consequently, increased numbers of activated T and B cells during the course of infection. The findings that glycyrrhizin, a specific inhibitor of extracellular high-mobility group box-1 (HMGB-1) abrogated this effect and that SP-A inhibits HMGB-1 release from immune cells suggest that SP-A inhibits M. pneumoniae-induced DC maturation by regulating HMGB-1 cytokine activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.